Dofetilide Capsules 500 mcg (0.5mg), 60-count bottle, Rx Only, Manufactured by Sun Pharmaceutical Industries Limited, Survey No. 259/15, Dadra-396 191, (U.T of D & NH), India, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512. NDC 47335-063-86

Out of Specification result observed in content uniformity testing

Recall #: D-1082-2023
Affected scope: 360 60-count bottles
Initiated: July 18, 2023

Compiled from official public sources by the publisher. · Updated September 2026

Sun Pharmaceutical Industries INC recalled Dofetilide Capsules 500 mcg (0.5mg), 60-count bottle, Rx Only, Manufactured by Sun Pharma… - a low-severity action.

Dofetilide Capsules 500 mcg (0.5mg), 60-count bottle, Rx Only, Manufactured by Sun Pharma… was recalled by Sun Pharmaceutical Industries INC in August 16, 2023. Reason: Out of Specification result observed in content uniformity testing. Check the official notice for the remedy. Verify recall #D-1082-2023 with the FDA Drug before acting.

The recall

Sun Pharmaceutical Industries INC issued this low-severity FDA Drug recall-Out of Specification result observed in content uniformity testing.

Low
severity level: Class III
classification: August 16, 2023
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1082-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Dofetilide Capsules 500 mcg (0.5mg), 60-count bottle, Rx Only, Manufactured by Sun Pharmaceutical Industries Limited, Survey No. 259/15, Dadra-396 191, (U.T of D & NH), India, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512. NDC 47335-063-86

Reason for recall

Out of Specification result observed in content uniformity testing

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Low (Class III)
Status	Terminated
Recall number	D-1082-2023
Date reported	August 16, 2023
Date initiated	July 18, 2023
Recalling firm	Sun Pharmaceutical Industries INC
Firm location	Princeton, NJ
Affected scope	360 60-count bottles
Distribution	Nationwide in the USA

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-1082-2023) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Out of Specification result observed in content uniformity testing

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on August 16, 2023. Severity: Low. Recall number: D-1082-2023.

Where was the recalled product distributed? ▼

Distribution: Nationwide in the USA.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Low), closest by report date among other firms and states.

0.9% Sodium Chloride Injection USP, 1000 … 2023-08-16 Dilettante Mocha Cafe brand Dark Ephemere… 2023-08-23 Dilettante Mocha Cafe brand Light Ephemer… 2023-08-23 Dilettante Mocha Cafe brand Dark Raspberr… 2023-08-23

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Cromolyn Sodium Oral Solution (Concentrat… 2023-08-09 rocuronium50 mg/5 mL (10 mg/mL), Syringes… 2023-08-09 vancomycin 1 g/250 mL added to 0.9% sodiu… 2023-08-09 succinylcholine 200 mg/10 mL (20 mg/mL), … 2023-08-09

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported August 16, 2023. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026